Response to: Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study' by Wang.

ABSTRACT:

SUBMITTER: Smeenk MM 

PROVIDER: S-EPMC12306307 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature